AG01 是一种抗颗粒蛋白前体 (GP88) 单克隆抗体,可抑制三阴性乳腺癌 (TNBC) 细胞增殖和迁移,降低磷酸化蛋白激酶 p-Src、p-AKT 和 p-ERK 的表达以及 Axl、c-MET、HIF-1α 和 VEGF 等致癌蛋白的表达,并在 TNBC 异种移植小鼠模型中抑制肿瘤生长和体内 Ki67 的表达,因此可用于 TNBC 等癌症的研究。
AG01
产品编号: MS-Q48073 纯度: 95.10% 分子量: 147.60 kDa
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

AG01 是一种抗颗粒蛋白前体 (GP88) 单克隆抗体,可抑制三阴性乳腺癌 (TNBC) 细胞增殖和迁移,降低磷酸化蛋白激酶 p-Src、p-AKT 和 p-ERK 的表达以及 Axl、c-MET、HIF-1α 和 VEGF 等致癌蛋白的表达,并在 TNBC 异种移植小鼠模型中抑制肿瘤生长和体内 Ki67 的表达,因此可用于 TNBC 等癌症的研究。

生物实验数据

生物活性 AG01 is an anti-progranulin (GP88) monoclonal antibody that inhibits the proliferation and migration of triple-negative breast cancer (TNBC) cells, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK as well as oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF, and suppresses tumor growth and in vivo Ki67 expression in TNBC xenograft mouse models, making it useful for research on cancers such as TNBC.
IC50 & Target

ERK1

 

ERK2

 

MMP-2

 

Axl

 

HIF-1α

 

体外研究
(In Vitro)

AG01 (0-300 µg/mL,48-72 小时) 可抑制 MDA-MB-231 和 HS578-T 细胞增殖,降低 Ki67 阳性细胞核数量。
AG01 (0-100 µg/mL,5 小时) 可抑制 MDA-MB-231 和 HS578-T 细胞迁移和侵袭。
AG01 (100 µg/mL,24-72 小时) 可降低 MDA-MB-231 和 HS578-T 细胞中 AKt、Src、Erk1/2 的磷酸化状态。
AG01 (100 µg/mL,24-72 小时) 在 MDA-MB-231、HS578-T 细胞中可降低 Axl、c-MET、ICAM-1、MMP-2、SNAIL、HIF-1α、VEGF、内源性前颗粒蛋白、SPARC、细胞粘附和迁移蛋白-纤连蛋白的表达。

Cell Proliferation Assay

Cell Line: MDA-MB-231, HS578-T cells
Concentration: 0, 25, 50, 100, 200, 300 µg/mL
Incubation Time: 48, 72 h
Result: Inhibited cells proliferation, resulted in a dose-dependent inhibition of MDA-MB-231 and HS578-T cells proliferation by 44% and 51% at 300 µg/mL compared with control.

Cell Migration Assay

Cell Line: MDA-MB-231, HS578-T cells
Concentration: 25, 50, 100 µg/mL
Incubation Time: 5 h
Result: Inhibited cells migration in a dose-dependent, with the highest reduction of 78.2%, 77.5% at 100 µg/mL for MDA-MB-231, HS578-T cells.

Western Blot Analysis

Cell Line: MDA-MB-231, HS578-T cells
Concentration: 100 µg/mL
Incubation Time: 24, 48, 72 h
Result: Decreased the phosphorylation status of Akt (14.8%), Src (23.6%), and Erk1/2 (20.3%) at 24 h and decreased phosphorylation of Akt (63%), Src (55.4%), and Erk1/2 (55.2%) at 72 h compared to control, decreased the ratio of phosphorylated protein to its total corresponding protein expression for Akt (71.9%), Src (49.8%), and Erk1/2 (62%) at 72 h in MDA-MB-231 cells.
Decreased the phosphorylation status of Akt (44.5%), Src (31.5%), and ERK1/2 (35.5%) at 24 h while decreased FAK phosphorylation (44.5%) at 48 h, decreased the ratio of phosphorylated protein to its total corresponding protein expression for p-Src/Src (44.3%), p-Akt/Akt (47.3%), and p-ERK1/2/ERK (46%) at 48 h in HS578-T cells.
Reduced c-MET expression of 59.7%.
Reduced SNAIL expression of 23.3% and 89%, ICAM-1 of 93.8% and 33.8%, AXL of 13.2% and 33.4% in MDA-MB-231 and HS578-T cells, respectively, reduced endogenous progranulin level in time-dependent reduction with MDA-MB-231 showing 37.7% reduction by 72 h and HS578-T showing almost a 100% reduction by 48 h.
Reduced cell adhesion and migratory protein-fbronectin in time-dependent decrease of 25.4% at 72 h as compared to its control lysate in MDA-MB-231 cells.
体内研究
(In Vivo)

AG01 (10 mg/kg,腹腔注射,每周两次,共 40 天) 可抑制 MDA-MB-231 异种移植裸鼠模型中的肿瘤生长和 Ki67 表达。

Animal Model: MDA-MB-231 (1.5x106) xenograft nude mice (6-8-week-old, female) model
Dosage: 10 mg/kg
Administration: i.p., twice weekly, 40 days
Result: Reduced Vt/V0 ratio and tumor weights by 50% compared to control human IgG treated group, reduced Ki67 expression in tumor sections by 52.5% compared to control groups, showed a 50% reduction of the mitotic index compared to control and 65% reduction of relative microvessel numbers compared to control HuIgG-treated animals.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT05627960A&G Pharmaceutical Inc.|University of Maryland Greenebaum Cancer Center
Triple Negative Breast Cancer|Hormone-Resistant Breast Cancer|Non Small Cell Lung Cancer|Mesothelioma
2022-02-14PHASE1
NCT02816827Vedic Lifesciences Pvt. Ltd.|Enovate Biolife Pvt Ltd
Mental Fatigue
2016-03NA
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 147.60 kDa

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础